How do healthtech startups run clinical validation?

Clinical validation in healthtech moves slower than consumer tech because founders face regulatory hurdles that traditional software companies don't [Ep 55]. The standard approach involves an MVP, followed by pilot programmes with clinical partners, before formal evidence generation work [#345]. But randomised control trials are expensive and time-consuming, which is why pragmatic alternatives are emerging [#435].

Early clinical partnerships matter. Founders benefit from building with clinical collaborators from the outset rather than bolting validation onto a finished product [Ep 55]. The sequencing is tight: pilots prove feasibility, then evidence work defines efficacy. The real constraint is capital. Startups burn through runway while approval and contracting processes move glacially. A delayed board decision or a rescheduled agenda item can derail timelines entirely, creating real pressure on founders with six months of funding left [#432]. The healthtech VC world now has clearer structures around evidence generation than it did a decade ago [#144], but the process itself remains fundamentally slower than consumer tech because the cost of being wrong in healthcare is not abstract.